Organization & Developments: NGM Bio

Parents

2017: Pursuing Larger Rivals, NGM Bio Tries To Make Mark On Fatty Livers
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: Merck Doesn't Want To Be Left Out Of The NASH Race Either, Uses Option Agreement - Merck & Co Inc. (NYSE:MRK)
2019: NGM Biopharmaceuticals And NGM282 In Primary Biliary Cirrhosis: A Rapid Clinical Benefit_seekingalpha.com
2019: NGM Biopharmaceuticals And NGM282 In Primary Sclerosing Cholangitis, And The Market Assessment_seekingalpha.com
2019: NGM NASH Data Was Preliminary, But More Important Biopsy Data On Its Way Early 2020_seekingalpha.com
2021: NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
Focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.